Celyad Competitors and Similar CompaniesClear all
Celyad's competitors and similar companies include Alnylam and Sorrento Therapeutics.
 Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
| |
Founding Date | Founding Date 2007 | Founding Date 2002 | Founding Date 2006 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations San Diego, US HQ San Diego, US | |
Employees | Employees 1751% decrease | Employees 1,32324% increase | Employees 31019% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 36.5 b | Valuation ($) 1.9 m |
Financial | |||
Revenue (est.) | Revenue (est.) €102k (FY, 2023) | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $62.8m (FY, 2022) |
Cost of goods | Cost of goods €69k (FY, 2023) | Cost of goods $268.2m (FY, 2023) | Cost of goods N/A |
Gross profit | Gross profit €1.4m (FY, 2023) | Gross profit $1.6b (FY, 2023) | Gross profit N/A |
Net income | Net income (€8.4m) (FY, 2023) | Net income ($440.2m) (FY, 2023) | Net income ($577.8m) (FY, 2022) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 1.5b | Total funding raised $ 42.6m |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companySorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View company